½ÃÀ庸°í¼­
»óǰÄÚµå
1372564

¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® ´ë»ó ¹üÀ§ : Á¦Ç° À¯Çüº°, ¿¬·ÉÃþº°, ÃÖÁ¾»ç¿ëÀÚº°

US Hydrocephalus Shunts Market Size and Forecasts, Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product, Type, Age Group, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 68 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ±Ô¸ð´Â 2022³â 1¾ï 900¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 1¾ï 4,600¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå °³¿ä :

¼öµÎÁõ¿¡´Â ¾Æ·¡¿Í °°Àº Ä¡·á¹ýÀÌ ÀÖ½À´Ï´Ù. :

¼ÇÆ® ½Ã½ºÅÛ : ¼ÇÆ® ½Ã½ºÅÛ : À̰ÍÀº ÀϹÝÀûÀÎ Ä¡·á¹ýÀ¸·Î, ¼ÇÆ®(°¡´Â °ü)¸¦ ¸Å¸³, ¿©ºÐÀÇ ³úô¼ö¾×À» ³ú·ÎºÎÅÍ Èí¼ö °¡´ÉÇÑ ´Ù¸¥ ºÎÀ§·Î ¿ìȸ½Ãŵ´Ï´Ù. ¼ÇÆ® ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ À¯È¿¼ºÀÌ Çâ»óÇϰí, ÇÕº´ÁõÀÌ °¨¼ÒÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

³»½Ã°æÀû Á¦3³ú½Ç Àý°³¼ú(ETV) : ³úÀÇ Á¦3³ú½Ç ¹Ù´Ú¿¡ ÀÛÀº ±¸¸ÛÀ» ¶Õ¾î ¿©ºÐÀÇ ³úô¼ö¾×À» ¹èÃâÇϰí Èí¼öÇÏ´Â ¼ö¼ú¹ýÀ¸·Î, ETV´Â ºñÀü¿°¼º ¼öµÎÁõÀÇ Æ¯Á¤ °æ¿ì¿¡ »ç¿ëµË´Ï´Ù.

Ä«Å×ÅÍ¿¡ ÀÇÇÑ ³ú½Ç ´©°ø¼ú: ³ú½Ç¿¡ Á÷Á¢ Ä«Å×Å͸¦ »ðÀÔÇÏ¿© ¿©ºÐÀÇ ³úô¼ö¾×À» ¹èÃâÇÏ´Â ¹æ¹ýµµ ÀÖ½À´Ï´Ù.

³ú½Ç ³»½Ã°æ °Ë»ç: ³»½Ã°æ°ú °°Àº Àúħ½ÀÀû ±â¼úÀÇ ¹ßÀüÀ¸·Î ¼öµÎÁõÀ» º¸´Ù Á¤È®ÇÏ°Ô Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¼öµÎÁõ Ä¡·á¸¦ À§ÇÑ ÆÄÆ®³Ê½Ê È®´ë

¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ±â¾÷Àº ½ÃÀå Á¡À¯À²À» È®´ëÇϱâ À§ÇØ ÇÕÀÛ ÅõÀÚ ¹× ÆÄÆ®³Ê½Ê°ú °°Àº Àü·«À» ½ÇÇàÇϰí ÀÖÀ¸¸ç, 2020³â Aesculap, Inc.´Â Christoph Miethke GmbH & Co.KG(MIETHKE)¿Í Çù·ÂÇÏ¿© M.blue ¼öµÎÁõ ¹ëºêÀÇ ¹Ì±¹ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. M.blue ¼öµÎÁõ ¹ëºê´Â °íÁ¤½Ä Â÷¾Ð Àåºñ¸¦ ¹ëºê¿¡ ÅëÇÕÇÑ µ¶ÀÚÀûÀÎ Áß·Â ±â¼úÀ» ÅëÇØ ȯÀÚ°¡ °¡Àå Ȱµ¿ÀûÀÎ ½Ã°£´ë¿¡ °³±¸ºÎ ¾Ð·ÂÀ» ½±°í À§Ä¡º°·Î Á¶ÀýÇÒ ¼ö ÀÖ´Â ¹ëºêÀÔ´Ï´Ù. ¸¹Àº ½ÃÀå °ü°èÀÚµéÀÌ ½Ã°£ °æ°ú¿¡ µû¸¥ À¯·®°ú ºÎÇǸ¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â '½º¸¶Æ® ¼ÇÆ®' °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠ¾÷°è ÆÄÆ®³ÊµéÀº ¼ÇÆ® ±â´É Àå¾Ö¸¦ Áø´ÜÇϱâ À§ÇØ ¿øÀ§ºÎ Ä«Å×Å͸¦ Åë°úÇÏ´Â À¯·®À» ÃßÁ¤Çϱâ À§ÇØ ¿­ Èñ¼®À» »ç¿ëÇÏ´Â Àåºñ¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ¼öµÎÁõ ¼ÇÆ®ÀÇ ½º¸¶Æ®ÇÑ ±â´ÉÀ» Áö¿øÇϱâ À§ÇÑ ÆÄÆ®³Ê½Ê Áõ°¡´Â ÇâÈÄ ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼©Æ® ǰÁú Çâ»óÀ» À§ÇÑ Á¶»ç Áõ°¡

¿¬±¸ÀÚµéÀº ¸·Èû, °¨¿° ¹× ±âŸ ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ °³¼±µÈ ¼ÇÆ® Àç·á¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù.

Ç×±Õ ÄÚÆÃ: ¿¬±¸ÁøÀº Ç×±Õ Æ¯¼ºÀ» °¡Áø ¼ÇÆ®¿ë ÄÚÆÃÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÄÚÆÃÀº ¼ÇÆ® »ðÀԽà °¨¿° À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Æó»ö ¹æÁö ¸ÞÄ¿´ÏÁò : ÀϺΠ¼ÇÆ® ¼³°è¿¡´Â ¸·ÈûÀ» ¹æÁöÇϰųª ¿ÏÈ­ÇÏ´Â ±â´ÉÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î »çÀÌÆÝ ¹æÁö ¸ÞÄ¿´ÏÁòÀÌ ÀÖ´Â ¹ëºê´Â ÀûÀýÇÑ È帧À» À¯ÁöÇÏ°í °ú¹è¼ö ¹× ¸·ÈûÀ» ¹æÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¸¶±×³×ƽ ¹ëºê Á¶Á¤: ÀϺΠ¼ÇÆ® ½Ã½ºÅÛÀº ÀÚ¼®À» »ç¿ëÇÏ¿© ºñħ½ÀÀûÀ¸·Î ¹ëºê ¼³Á¤À» Á¶Á¤ÇÏ¿© ¹Ýº¹ÀûÀÎ ¼ö¼úÀÇ Çʿ伺À» ÁÙÀÔ´Ï´Ù.

»ýü ÀûÇÕ¼º Àç·á: ¼ÇÆ® ±¸Á¶¿¡ »ýü ÀûÇÕ¼º Àç·á¸¦ »ç¿ëÇÏ¸é ¾Ë·¹¸£±â ¹ÝÀÀ ¹× ±âŸ ½Åü ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿ø°Ý ¸ð´ÏÅ͸µ: ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¼ÇÆ® ¼º´É°ú µÎ°³ ³»¾ÐÀ» ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÇ·áÁøÀÌ ¹®Á¦°¡ ½É°¢ÇØÁö±â Àü¿¡ ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

³ª³ë±â¼ú: ¹ÚÅ׸®¾Æ ºÎÂø¿¡ ÀúÇ×ÇÏ°í ¼ÇÆ® ÀüüÀÇ ³»±¸¼ºÀ» Çâ»ó½ÃŰ´Â ¼ÇÆ® ºÎǰÀ» ¸¸µé±â À§ÇØ ³ª³ë±â¼úÀÇ Àû¿ëÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î 2021³â Ææ½Çº£´Ï¾Æ ÁÖ¸³´ë ¿¬±¸ÁøÀº HydroFix¶ó´Â ȹ±âÀûÀÎ ±â¼úÀ» Àû±ØÀûÀ¸·Î ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ¼ö¼ú¿ë ¼ÇÆ® ½Ã½ºÅÛÀº ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ±âÁ¸ ¼ÇÆ® Àåºñ¿¡ ¼ö¹ÝµÇ´Â ¼ö¸¹Àº À§ÇèÀ» ÇØ°áÇϱâ À§ÇØ Æ¯º°È÷ °í¾ÈµÇ¾ú½À´Ï´Ù. ÁÖ¿ä ¸ñÀûÀº Á¤»ó¾Ð¼öµÎÁõ(NPH) ȯÀÚ¿¡°Ô Àå±âÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ±â¼úÀ» °³¹ßÇϱâ À§ÇØ ¿¬±¸ÁøÀº Cranial Devices Inc.¶ó´Â ½Å»ý ±â¾÷À» ¼³¸³Çß½À´Ï´Ù. ±×µéÀº ÇöÀç Ææ½Çº£´Ï¾Æ ÁÖ¸³´ëÇÐÀ¸·ÎºÎÅÍ HydroFix ±â¼ú ¶óÀ̼±½º¸¦ ÃëµæÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¸¶Âù°¡Áö·Î, ÀÓ»ó ´Ü°èÀÇ ÀÇ·á±â±â ȸ»çÀÎ Rhaeos, Inc.´Â ƯÇã ±â¼úÀÎ FlowSense¿Í ºñħ½ÀÀû ¹«¼± ¿þ¾î·¯ºí ÇǺΠÆÐÄ¡¸¦ °³¹ßÇϰí ÀÖÀ¸¸ç, FlowSense´Â ¹«¼± ºñħ½ÀÀû ¿­ À¯·® ¼¾¼­·Î ¼ÇÆ® »óºÎ¿¡ ÀåÂøÇÏ¿© ȯÀÚÀÇ °æºÎ¿¡ ºÎÂøÇÏ¿© ¼ö¾×ÀÇ Á¸Àç¿Í Å©±â¸¦ °¨ÁöÇÕ´Ï´Ù. FlowSense¸¦ ÅëÇØ ¼ÇÆ® »óºÎ, ÀÔ¿ø ȯÀÚ, ÀÀ±Þ½Ç¿¡¼­ ¼ÇÆ® ±â´ÉÀ» ¸ð´ÏÅ͸µÇÏ¿© ºÒÇÊ¿äÇÑ ¿µ»óÁø´Ü, ÀÔ¿ø ±â°£, ÀçÀÔ¿ø ºñ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ºÎ¹®º° °³¿ä

¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀÇ ¼ºÀåÀº Á¦Ç°, À¯Çü, ¿¬·É´ë, ÃÖÁ¾»ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù. Á¦Ç°º°·Î´Â ¼öµÎÁõ ¹ëºê, ¼öµÎÁõ Ä«Å×ÅÍ, ½Å°æ ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ¼öµÎÁõ ¹ëºê´Â ´Ù½Ã ¾Ð·Â Á¶Àý ¹ëºê, °íÁ¤ ¾Ð·Â ¹ëºê·Î ³ª´¹´Ï´Ù. À¯Çüº°·Î ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀº ½É½Çº¹¸·, ½É½Ç½ÉÀå, ½É½Ç½Å°æ, ¿äÃߺ¹¸·À¸·Î ±¸ºÐµË´Ï´Ù. ½É½Çº¹¸· ºÎ¹®Àº 2022³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ½É½Çº¹¸·(VP) ¼ÇÆ®´Â ³ú½Ç¿¡¼­ º¹¸·°­(¼ÒÈ­±â°ü¿¡ °¡±î¿î º¹ºÎÀÇ È¨)À¸·Î ¼ö¾×À» ¿ìȸ½ÃÄÑ Ã¼¾× ÃàÀûÀ¸·Î ÀÎÇÑ ³ú¿¡ °¡ÇØÁö´Â ¾Ð·ÂÀ» °¨¼Ò½Ãŵ´Ï´Ù. º¹°­ ¼ÇÆ®´Â ¼öµÎÁõ Ä¡·á¿¡ °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¼ÇÆ® Áß ÇϳªÀÔ´Ï´Ù. ¹Ì±¹ ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)¿¡ °ÔÀçµÈ ¿¬±¸ ³í¹®¿¡ µû¸£¸é VP ¼ÇÆ®´Â °í±Þ ½Å°æ¿Ü°ú ȯÀÚ Ä¡·á¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡¸ç, ¾ç¼º Áúȯ¿¡¼­ VP ¼ÇÆ®´Â »ý¸íÀ» ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀº ¿¬·É´ëº°·Î ¼Ò¾Æ ¹× ¼ºÀÎÀ¸·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â ¼Ò¾Æ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí 2030³â±îÁö ¿¹Ãø ±â°£ Áß ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼öµÎÁõÀº ¼Ò¾Æ ³ú¼ö¼úÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀÔ´Ï´Ù. ¼ºÀå±â žÆÀÇ ¼öµÎÁõÀ» È®ÀÎÇϱâ À§ÇØ »êÀü ÃÊÀ½ÆÄ ¶Ç´Â MRI °Ë»ç°¡ ±ÇÀåµË´Ï´Ù. ¿µ¾Æ¿¡¼­´Â ÀϹÝÀûÀ¸·Î ÁøÇ༺ ´ëµÎÁõÀÇ Â¡Èİ¡ ³ªÅ¸³ª¸ç, 2¼¼ ÀÌ»óÀÇ ¼Ò¾Æ¿¡¼­´Â µÎ°³³»¾Ð»ó½ÂÁõÀÇ Â¡ÈÄ¿Í Áõ»óÀÌ ³ªÅ¸³³´Ï´Ù. ¼Ò¾Æ ¼öµÎÁõÀº ¹æÄ¡Çϸé À§ÇèÇÕ´Ï´Ù. ±×·¯³ª Á¶±â Áø´Ü°ú Ä¡·á¸¦ ÅëÇØ ¸¹Àº °æ¿ì ¾ÆÀ̵éÀº ±ÔÄ¢ÀûÀÌ°í °Ç°­ÇÑ »îÀ» »ì ¼ö ÀÖ½À´Ï´Ù. ¼öµÎÁõ Çùȸ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¾Æ±â 1,000¸í Áß 1-2¸íÀÌ ¼öµÎÁõÀ» ¾Î°í ÀÖ½À´Ï´Ù.

¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚº°·Î º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¹× ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â±îÁö ¿¹Ãø ±â°£ Áß¿¡µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿øÀº º¹ÀâÇÏÁö¸¸ Àü¹®ÀûÀÎ °úÇÐ Àåºñ¸¦ ÅëÇØ »ç¶÷µé¿¡°Ô ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³Àº ÀϹÝ, Àü¹® ¹× Á¤ºÎ ±â°üÀ¸·Î ºÐ·ùµË´Ï´Ù. º´¿øÀº ´Ù¾çÇÑ Áúº´À¸·Î °íÅë¹Þ´Â ȯÀÚ Áý´Ü¿¡°Ô ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀÇ º´¿ø ºÎ¹®ÀÇ ¼ºÀåÀº ½Å°æ°è ¼ö¼ú °Ç¼ö Áõ°¡¿Í ÀÌ·¯ÇÑ ½Ã¼³¿¡¼­ ¼öµÎÁõ Ä¡·á¸¦ À§ÇÑ ¹ëºê ¹× ½Å°æ ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ¼±Áø±¹°ú ½ÅÈï ±¹°¡¿¡¼­ ¼öµÎÁõ ¼ö¼úÀ» Á¦°øÇÏ´Â º´¿øÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ÁÖ¿ä Âü¿© ±â¾÷

B.B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc, Natus Medical Inc, Anuncia Inc, Desu Medical µîÀÌ ¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå¿¡ °üÇÑ ¸®Æ÷Æ® ÀÛ¼º½Ã¿¡ ÂüÁ¶ÇÑ ÁÖ¿ä 1Â÷ Á¤º¸¿ø ¹× 2Â÷ Á¤º¸¿øÀ¸·Î¼­´Â ¼¼°èº¸°Ç±â±¸(WHO), FDA(½ÄǰÀǾ౹), ¼öµÎÁõ Çùȸ, ±¹¸³ ½Å°æÁúȯ ³úÁ¹Áß ¿¬±¸¼Ò(NINDS), ͏®Æ÷´Ï¾Æ ´ëÇÐ ·Î½º¾ØÁ©·¹½º±³º¸°Ç ±â±¸, ±¹¸³ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö Á¤º¸ ¼¾ÅÍ, ¿À·»Áö±º ¼Ò¾Æ º¸°Ç ¼¾ÅÍ µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦3Àå ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå - ½ÃÀå ±¸µµ

  • °³¿ä
    • ¹Ì±¹ÀÇ PEST ºÐ¼®

Á¦4Àå ¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¼öµÎÁõÀÇ ±ÞÁõ
    • ¼öµÎÁõ °ü¸® µð¹ÙÀ̽ºÀÇ Áøº¸
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • Ä¡·áºñ »ó½Â°ú Àç¼ö¼úÀÇ Çʿ伺
  • ½ÃÀå ±âȸ
    • ¼öµÎÁõ ¼ÇÆ®¿¡ °üÇÑ ¿¬±¸°³¹ß ¹× ½ÃÇè¿¡ ´ëÇÑ ÀÚ±Ý Á¦°øÀÇ Áõ°¡
  • ÇâÈÄ µ¿Çâ
    • ¼öµÎÁõ ¼ÇÆ® ½º¸¶Æ®ÇÑ ±â´ÉÀ» Áö¿øÇÏ´Â ÆÄÆ®³Ê½ÊÀÇ Áõ°¡
  • ¿µÇ⠺м®

Á¦5Àå ¹Ì±¹ÀÇ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦6Àå ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : Á¦Ç°º°

  • ¼­·Ð
  • ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå 2022³â ¹× 2030Á¦Ç°º° ÆÇ¸Å°í Á¡À¯À²(%)
  • ¼öµÎÁõ ¹ëºê
  • ¼öµÎÁõ Ä«Å×ÅÍ
  • ½Å°æ ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ
  • ±âŸ

Á¦7Àå ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : À¯Çüº°

  • ¼­·Ð
  • ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå 2022³â ¹× 2030À¯Çüº° ÆÇ¸Å°í Á¡À¯À²(%)
  • º¹°­ ¼ÇÆ®
  • º¹°­ ¼ÇÆ®
  • ³ú½Ç º¹¸· ¼ÇÆ®
  • ¿äÃß º¹¸·

Á¦8Àå ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ¿¬·ÉÃþº°

  • ¼­·Ð
  • ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå 2022³â ¹× 2030 ¿¬·ÉÃþº° ÆÇ¸Å°í Á¡À¯À²(%)
  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦9Àå ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • ¹Ì±¹ ¼öµÎÁõ ¼ÇÆ® ½ÃÀå 2022³â ¹× 2030ÃÖÁ¾»ç¿ëÀÚº° ÆÇ¸Å°í Á¡À¯À²(%)
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦10Àå ¾÷°è »óȲ

  • ¼­·Ð
  • À¯±âÀû °³¹ß
  • °³¿ä

Á¦11Àå ±â¾÷ °³¿ä

  • B. Braun SE
  • Sophysa SA
  • Integra LifeSciences Holdings Corp
  • KANEKA MEDIX CORP.
  • Medtronic Plc
  • Natus Medical Inc
  • Anuncia Inc.
  • Desu Medical

Á¦12Àå ºÎ·Ï

KSA 23.11.09

The US Hydrocephalus Shunts market size is expected to reach US$ 0.146 billion by 2030 from US$ 0.109 billion in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030.

Market Overview:

There are several treatment options available for hydrocephalus, including:

Shunt Systems: This is a common treatment where a shunt (a thin tube) is implanted to divert excess cerebrospinal fluid from the brain to another part of the body where it can be absorbed. There may have been advancements in shunt technology to improve their effectiveness and reduce complications.

Endoscopic Third Ventriculostomy (ETV): This is a surgical procedure where a small hole is made in the floor of the third ventricle of the brain to allow excess cerebrospinal fluid to flow out and be absorbed. ETV is used in certain cases of non-communicating hydrocephalus.

Ventriculostomy with Catheter: Another surgical option involves inserting a catheter directly into the brain's ventricles to drain excess cerebrospinal fluid.

Intraventricular Endoscopy: Advances in minimally invasive techniques like endoscopy have allowed for more precise diagnosis and treatment of hydrocephalus.

Increasing Partnerships to Treat Hydrocephalus

US hydrocephalus shunts market companies are implementing strategies such as joint ventures and partnerships to extend their market shares. In 2020, Aesculap, Inc., partnered with Christoph Miethke GmbH & Co. KG (MIETHKE), and together they announced the launch of the M.blue hydrocephalus valve in the US. Its unique gravity technology is integrated with a fixed differential pressure unit in a valve, enabling a simple, position-dependent adjustment of the opening pressure during the patient's most active time. Many market players are focused on developing "smart shunts" that could provide an understanding of flow or volume rates over time. Several industry partners are also developing devices that use thermodilution to estimate flow through a distal catheter to diagnose shunt malfunction. Thus, the increasing number of partnerships to aid in smart functioning of hydrocephalus shunts would lead to new future trends in the US hydrocephalus shunts market.

Growing Research to Improve the Quality of Shunts

Researchers have been developing improved shunts materials to reduce the risk of blockages, infections, and other complications.

Antibacterial Coatings: Researchers have been investigating coatings for shunts that have antibacterial properties. These coatings can help reduce the risk of infection when the shunt is implanted.

Anti-Blockage Mechanisms: Some shunt designs incorporate features to prevent or mitigate blockages. For example, valves with anti-siphon mechanisms can help maintain proper flow and prevent over-drainage or blockages.

Magnetic Valve Adjustments: Some shunt systems use magnets to adjust valve settings non-invasively, reducing the need for repeated surgeries.

Biocompatible Materials: The use of biocompatible materials in shunt construction can minimize the risk of allergic reactions or other adverse responses from the body.

Remote Monitoring: Advancements in remote monitoring technology have allowed for tracking shunt performance and intracranial pressure, helping healthcare providers identify issues before they become severe.

Nanotechnology: Nanotechnology applications have been explored for creating shunt components that resist bacterial adhesion and improve the overall durability of the shunt.

For instance, in 2021, Penn State researchers have been actively working on a groundbreaking technology called HydroFix. This innovative surgical shunt system is specifically designed to address the numerous risks associated with existing shunt devices available in the market. Its primary aim is to offer a long-lasting treatment solution for patients with Normal Pressure Hydrocephalus (NPH). To advance this technology, the researchers established a startup called Cranial Devices Inc. They are currently in the process of seeking a license for the HydroFix technology from Penn State University.

Similarly, Rhaeos, Inc., a clinical-stage medical device company, is developing FlowSense, a patented technology and a noninvasive wireless, wearable skin patch. FlowSense is a wireless, noninvasive thermal flow sensor that is mounted on a patient's neck overlying the shunt to detect the presence and magnitude of CSF. With FlowSense, shunt function can be monitored in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.

US Hydrocephalus Shunts Market: Segmental Overview

The US hydrocephalus shunts market growth is segmented into product, type, age group, and end-user. On the basis of product, the market is segmented into hydrocephalus valves, hydrocephalus catheters, neuronavigation systems, and others. The hydrocephalus valves is further segmented into adjustable pressure valves, and fix pressure valves. In terms of type, the US hydrocephalus shunts market is segmented into ventriculoperitoneal, ventriculoatrial, ventriculopleural, and lumboperitoneal. The ventriculoperitoneal segment led the market in 2022 and is expected to retain its dominance during the forecast period. A ventriculoperitoneal (VP) shunt reduces pressure exerted on the brain by fluid accumulation by diverting CSF from the brain's ventricles into the peritoneal cavity, the slot in the abdomen near digestive organs. Ventriculoperitoneal (VP) shunts are among the most commonly used tools for treating hydrocephalus. According to a research paper published in the National Center for Biotechnology Information (NCBI), a VP shunt has a high impact in advanced neurosurgical patient care. VP shunt can be lifesaving for benign disorders.

The US hydrocephalus shunts market, by age group, is segmented into pediatric and adults. The pediatric segment led the market in 2022 and is expected to retain its dominance during the forecast period by 2030. Hydrocephalus is the most common cause of brain surgery in children. A prenatal sonogram or MRI scan is recommended to identify hydrocephalus in a growing fetus. Infants generally show signs of progressive macrocephaly, whereas children older than 2 years show signs and symptoms of intracranial hypertension. Pediatric hydrocephalus can be dangerous if left untreated. Nevertheless, with early diagnosis and treatment, children often lead regular and healthy lives. According to the Hydrocephalus Association, 1-2 of every 1,000 babies have hydrocephalus in the US.

The US hydrocephalus shunts market, by end user, is segmented into hospitals, ambulatory surgical centers, others. The hospitals segment led the market in 2022 and is expected to retain its dominance during the forecast period by 2030. Hospitals provide healthcare to people through complicated but specialized scientific equipment. These facilities are classified into general, specialty, or government organizations. Hospitals serve a significant role by providing medical services to patient populations suffering from various diseases. The growth of the US hydrocephalus shunt market for the hospitals segment is attributed to an increase in the number of neurological surgeries, and a surge in demand for valves and neuronavigation systems in these facilities to treat the condition. Additionally, an increasing number of hospitals providing hydrocephalus surgeries in developed and developing countries is expected to boost the market growth in the future.

US Hydrocephalus Shunts Market: Key Players

B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc, Natus Medical Inc, Anuncia Inc, Desu Medical are among the leading companies operating in the US hydrocephalus shunts market.

A few of the key primary and secondary sources referred to while preparing the report on the US hydrocephalus shunts market are the World Health Organization (WHO), FDA (Food and Drug Administration), Hydrocephalus Association, National Institute of Neurological Disorders and Stroke (NINDS), University of California, Los Angeles Health Organization, National Center for Biotechnology Information, Children's Health Orange County, amongst others.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the hydrocephalus shunts market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US hydrocephalus shunts market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth US market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Research Methodology

  • 2.1 Coverage
  • 2.2 Secondary Research
  • 2.3 Primary Research

3. US Hydrocephalus Shunts Market - Market Landscape

  • 3.1 Overview
    • 3.1.1 US PEST Analysis

4. US Hydrocephalus Shunts Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Surging Prevalence of Hydrocephalus
    • 4.1.2 Advancements in Hydrocephalus Management Devices
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Treatments and Need for Revised Surgeries
  • 4.3 Market Opportunities
    • 4.3.1 Rise in Funding for R&D and Trials Associated with Hydrocephalus Shunts
  • 4.4 Future Trends
    • 4.4.1 Increasing Partnerships to Aid in Smart Functioning of Hydrocephalus Shunts
  • 4.5 Impsact Analysis

5. US Hydrocephalus Shunts Market - Country Analysis

  • 5.1 US Hydrocephalus Shunts Market
    • 5.1.1 Overview

6. Hydrocephalus Shunts Market - Revenue and Forecast to 2030 - by Product

  • 6.1 Overview
  • 6.2 US Hydrocephalus Shunts Market Revenue Share, by Product 2022 & 2030 (%)
  • 6.3 Hydrocephalus Valves
    • 6.3.1 Overview
    • 6.3.2 Hydrocephalus Valves: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Adjustable Pressure Valves
        • 6.3.2.1.1 Overview
        • 6.3.2.1.2 Adjustable Pressure Valves: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.2 Fix Pressure Valves
        • 6.3.2.2.1 Overview
        • 6.3.2.2.2 Fix Pressure Valves: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Hydrocephalus Catheters
    • 6.4.1 Overview
    • 6.4.2 Hydrocephalus Catheters: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Neuronavigation Systems
    • 6.5.1 Overview
    • 6.5.2 Neuronavigation Systems: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)

7. US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 US Hydrocephalus Shunts Market Revenue Share, by Type 2022 & 2030 (%)
  • 7.3 Ventriculoperitoneal
    • 7.3.1 Overview
    • 7.3.2 Ventriculoperitoneal: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Ventriculoatrial
    • 7.4.1 Overview
    • 7.4.2 Ventriculoatrial: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Ventriculopleural
    • 7.5.1 Overview
    • 7.5.2 Ventriculopleural: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Lumboperitoneal
    • 7.6.1 Overview
    • 7.6.2 Lumboperitoneal: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)

8. US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 - by Age Group

  • 8.1 Overview
  • 8.2 US Hydrocephalus Shunts Market Revenue Share, by Age Group 2022 & 2030 (%)
  • 8.3 Pediatric
    • 8.3.1 Overview
    • 8.3.2 Pediatric: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Adults
    • 8.4.1 Overview
    • 8.4.2 Adults: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)

9. US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 US Hydrocephalus Shunts Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: US Hydrocephalus Shunts Market - Revenue and Forecast to 2030 (US$ Million)

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Developments
    • 10.2.1 Overview

11. Company Profiles

  • 11.1 B. Braun SE
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Sophysa SA
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Integra LifeSciences Holdings Corp
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 KANEKA MEDIX CORP.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Medtronic Plc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Natus Medical Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Anuncia Inc.
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Desu Medical
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦